Cash Strategies for Life Sciences Delays
By

The one constant when raising financing in a life sciences company is that it takes longer than initially forecasted.  As previously shared in my colleague Patrick Nugent’s article about Life Sciences Financing Trends, it is taking twice as long to close a financing round (six months or more), and the length of time…Read More

Read More
How to Successfully Extend the Cash Runway to Growth in Early Commercial Stage Life Science Companies
By ,

This article is the second in a 4-part series reviewing financing solutions for the Life Science sector. Life Science venture capital and private equity-funded startups are constantly chasing capital to extend operating cash runways, driving value inflection milestones such as clinical trial data and funding growth for commercial-stage entities. Understandably,…Read More

Read More
Trends in Financing in Life Sciences: 2024 Updates
By

This article is first in a 4-part series reviewing financing solutions for the Life Science sector. As we move into Q2 of 2024, the Fed continues to hold the line on interest rate declines. Capital markets remain tight and for companies in need of growth financing, this is problematic. This…Read More

Read More
Scaling for Growth: Building a Foundation for Your Company’s Next Inflexion Point
By

My career as a finance executive in both biotech and medtech Life Sciences companies has included many assignments where growth was imperative, despite prevailing countercurrents in the market and the challenges this imposed internally: At Lipid Sciences, a privately held biotechnology company pursuing HDL therapies for cardiac and viral applications,…Read More

Read More

More Posts